arrow
N

Nimira Alimohamed

university of calgary
H指数:17
被引数:1,545
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer

前瞻性多中心研究:循环肿瘤DNA与肿瘤组织指导FGFR靶向治疗在转移性尿路上皮癌中的应用

2026-02-270
OAAI
A population-based analysis of patterns of care in patients with de novo muscle-invasive bladder cancer from Alberta, Canada

一项基于人群的分析,研究加拿大艾伯塔省新发肌层浸润性膀胱癌患者的治疗模式。

2025-12-010
PRE
Effect of Sex Differences on Cancer Outcomes After Chemo-Radiation for Muscle-Invasive Bladder Cancer: A Retrospective Multicenter Cohort Study

性差异对肌肉浸润性膀胱癌化疗放疗后癌症结局的影响:一项回顾性多中心队列研究

2025-11-010
PRE
Development and International Evaluation of an Artificial Intelligence–based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non–muscle-invasive Bladder Cancer

基于人工智能的模型(PROGRxN-BCa)的开发与国际评估:使用世界卫生组织2004/2022分级系统预测进展风险并改善非肌层浸润性膀胱癌的亚分层

2025-10-070
PRE
A population-based analysis of patterns of care in patients with high-risk non-muscle-invasive bladder cancer from Alberta, Canada

来自加拿大阿尔伯塔省的高风险非肌层浸润性膀胱癌患者护理模式的人口基础分析

2025-10-011
OAAI
SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma

SGNDV-001: 西迪妥单抗维多汀联合帕博利珠单抗治疗表达HER2的局部晚期或转移性尿路上皮癌

2025-07-290
OA
Effect of Complete Transurethral Resection on Oncologic Outcomes After Radiation Therapy for Muscle-Invasive Bladder Cancer
2025-02-010
OAAI
Benefit of Neoadjuvant Cisplatin-based Chemotherapy for Invasive Bladder Cancer Patients Treated with Radiation-based Therapy in a Real-world Setting: An Inverse Probability Treatment Weighted Analysis
2024-12-012
OA
The Impact of Histologic Subtypes on Clinical Outcomes After Radiation-Based Therapy for Muscle-Invasive Bladder Cancer
2024-07-251
PRE
Description of a Multi-faceted COVID-19 Pandemic Physician Workforce Plan at a Multi-site Academic Health System
2021-02-096
OAAI
Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy
2016-08-01126
OAAI